Skip to content
Open access

Tempol Ameliorates Psoriatic Skin Inflammation: Evidence of TLR4/NF‐κB/Nrf2 Axis Modulation

Jan 2026 · Mediators of Inflammation · Vol 2026 · 0 citations · 66 references
Medicine

TL;DR

Tempol preserved tissue viability under psoriasiform conditions and significantly reduced Staphylococcus aureus (S. aureus) adhesion, and restored epidermal barrier integrity, as demonstrated by increased levels of tight junction and differentiation markers, even under infection‐associated conditions.

Abstract

Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyperproliferation, immune dysregulation, oxidative stress, and impaired epidermal barrier function. In the present study, we investigated the protective effects of Tempol, a membrane‐permeable nitroxide with antioxidant and anti‐inflammatory properties, using several psoriasiform models. In HaCaT keratinocytes, stimulation with a cytokine mixture significantly induced inflammatory responses. Tempol (0.5 and 1 mM) showed no cytotoxic effects and markedly reduced the mRNA and protein levels of proinflammatory cytokines, including TNF‐α, IL‐1β, and IL‐6. Tempol was associated with reduced expression of TLR4, MyD88, TRAF6, and nuclear factor‐kappa B (NF‐κB), together with restoration of IκBα expression, findings consistent with modulation of the TLR4/NF‐κB signaling pathway. In parallel, Tempol was associated with activation of the nuclear factor erythroid 2‐related factor 2 (Nrf2)/HO‐1 antioxidant axis, as evidenced by increased expression of Nrf2, HO‐1, and MnSOD, along with a reduction in the pro‐oxidant enzymes NOX2 and NOX4. These effects were associated with decreased oxidative damage, including reduced lipid peroxidation and nitric oxide production. Furthermore, Tempol exerted cytoprotective effects by restoring the balance between pro‐ and antiapoptotic markers, as indicated by increased Bcl‐2 levels, decreased Bax and p53 expression, and a reduced Bax/Bcl‐2 ratio. The anti‐inflammatory activity of Tempol was further confirmed in an imiquimod (IMQ)‐stimulated HaCaT/THP‐1 coculture model, where it significantly reduced the release of key immune mediators, including TLR4, IL‐8, IL‐17A, and IL‐23, highlighting its ability to modulate immune‐epithelial crosstalk. In a reconstructed human epidermis (RHE) model, Tempol preserved tissue viability under psoriasiform conditions and significantly reduced Staphylococcus aureus (S. aureus) adhesion. Importantly, Tempol restored epidermal barrier integrity, as demonstrated by increased levels of tight junction and differentiation markers, including ZO‐1, Occludin, Claudin‐1, and Filaggrin, even under infection‐associated conditions. Taken as a whole, these findings support the potential of Tempol as a promising therapeutic strategy for psoriasis and related inflammatory skin disorders.

Read PDF

Similar papers

Open access Sep 2026

Downregulating CHI3L2 via the STAT3 Pathway: The Mechanism of Calcitriol in Suppressing Psoriatic Inflammation and Keratinocyte Hyperproliferation

It is demonstrated that calcitriol ameliorates psoriatic inflammation and keratinocyte hyperproliferation through CHI3L2 downregulation mediated by the STAT3 pathway, highlighting CHI3L2 as a potential therapeutic target for psoriasis.

Qing-Qing He, Jun-Lin Liu · 0 citations
Sep 2026

Rhoifolin attenuates atopic dermatitis-like symptoms in mice by regulating PPARα-mediated NF-κB/NLRP3 inflammation and pyroptosis processes.

It is demonstrated that ROF exerts favorable inhibitory effects against AD-like inflammation both in vivo and in vitro, underscoring its potential as a viable therapeutic option for managing AD and other inflammatory cutaneous disorders.

Hui Li, Heng-Li Luo, Xin Zhang et al. · 0 citations
Open access Aug 2026

Topical febuxostat attenuates imiquimod-induced psoriasiform dermatitis and modulates NFE2L2 (NRF2)/NLRP3 mRNA expression

Topical febuxostat demonstrated significant antipsoriatic effects in the imiquimod-induced mouse model of psoriasiform dermatitis, accompanied by improvements in oxidative stress, inflammatory cytokines, and histopathological abnormalities, which support further investigation of topical febuxostat as a potential nonste...

H. T. Alamir, W. Albahadly, H. F. Al-zubaidy et al. · 0 citations
Aug 2026

Celastrol alleviates synovial inflammation and joint destruction in rheumatoid arthritis in association with Nrf2/HO-1/GPX4 pathway activation

It is suggested that CEL alleviates synovial inflammation and joint injury in experimental RA in association with Nrf2/HO-1/GPX4 pathway activation and suppression of TNF-α-stimulated rat FLS activation, supporting further investigation of CEL as a candidate antioxidant-oriented therapeutic agent for RA.

Yun-Ke Guo, Hao Tang, Aydana Musha et al. · 1 citation · ⚡1
Open access Sep 2026

Fisetin Attenuates Human Macrophage Polarization and Pro‐Inflammatory Responses via NLRP3 and NF‐κB/MAPK Suppression

ABSTRACT Natural compounds with anti‐inflammatory properties are increasingly explored as therapeutic agents due to their lower risk of side effects compared with conventional drugs. Fisetin, a dietary bioflavonol abundant in fruits and vegetables, exhibits anti‐inflammatory activity in several cell types, including mu...

Nattaya Onpan, C. Lorthongpanich, P. Kheolamai et al. · 0 citations
Open access Aug 2026

LCN2‐Driven Fibroblast Ferroptosis‐Associated Injury Promotes Keratinocyte Proliferation via Lipid Peroxidation Signaling in Psoriasis

In vivo and in vitro analyses showed that inflammatory stimulation induced ferroptosis‐related injury in dermal fibroblasts, as evidenced by increased lipid peroxidation, impaired antioxidant defenses, and characteristic ultrastructural alterations, and highlight stromal lipid peroxidation as a potential therapeutic ta...

Min Zhang, GuangDong Liu, Shu-Xin Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.